It is very clear that AMBS has a methodical stepwise plan to get to an uplist and beyond. The puzzle pieces are being assembled. From a strategic perspective, it was very smart to add to the pipeline with an acquisition (ESS) before what looks like a sale or significant transaction related to Lympro. Surprised there was not an actual PR about Dr. Lowe assuming the role of AMBS President, Europe. Still early.